Allogene Therapeutics, Inc.
ALLO
$1.77
-$0.09-4.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -23.50% | -36.25% | -36.33% | -30.30% | -20.25% |
| Gross Profit | 35.05% | 36.25% | 36.33% | 30.30% | 20.25% |
| SG&A Expenses | 45.92% | -6.02% | -11.25% | -15.89% | -11.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.29% | -29.30% | -29.90% | -26.45% | -18.07% |
| Operating Income | 13.81% | 29.30% | 29.90% | 26.45% | 18.07% |
| Income Before Tax | 16.23% | 28.67% | 34.77% | 37.55% | 23.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.23% | 28.67% | 35.25% | 37.55% | 23.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.23% | 28.67% | 35.25% | 37.55% | 23.23% |
| EBIT | 13.81% | 29.30% | 29.90% | 26.45% | 18.07% |
| EBITDA | 13.75% | 30.39% | 31.28% | 27.72% | 18.26% |
| EPS Basic | 44.26% | 36.09% | 39.67% | 41.15% | 33.36% |
| Normalized Basic EPS | 41.49% | 36.10% | 37.18% | 29.82% | 31.32% |
| EPS Diluted | 44.26% | 36.09% | 39.67% | 41.15% | 33.36% |
| Normalized Diluted EPS | 41.49% | 36.10% | 37.18% | 29.82% | 31.32% |
| Average Basic Shares Outstanding | 50.24% | 11.58% | 7.34% | 6.14% | 15.21% |
| Average Diluted Shares Outstanding | 50.24% | 11.58% | 7.34% | 6.14% | 15.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |